ADP-ribosylation factor-like protein 5 (ARL5), a member of the ADP-ribosylation factor family of GTP-binding proteins, plays a pivotal role in cellular processes including intracellular trafficking and membrane transport. ARL5 is particularly significant due to its involvement in the regulation of vesicle trafficking, a critical aspect of cellular homeostasis and functionality. This protein, like other members of the ARF/ARL family, cycles between an active GTP-bound state and an inactive GDP-bound state, a transformation that is essential for its role in cellular mechanisms. The precise biological functions of ARL5, though not fully elucidated, are believed to contribute significantly to the sorting and movement of proteins through the endosomal-lysosomal system. This function is crucial for the maintenance and remodeling of the endomembrane system of the cell, affecting various cellular outputs from nutrient uptake to the removal of cellular debris.
Activation of ARL5, like other GTPases, is primarily governed by its cycle between the GTP-bound active form and the GDP-bound inactive form. This cycling is regulated by specific guanine nucleotide exchange factors (GEFs) which facilitate the exchange of GDP for GTP, thus activating ARL5. On the other hand, GTPase-activating proteins (GAPs) accelerate the hydrolysis of GTP to GDP, rendering the protein inactive. The spatial and temporal regulation of ARL5 activity is critical, as it ensures that its activation occurs precisely where and when required for effective cargo sorting and transport. This regulated activation and deactivation cycle allows ARL5 to act as a molecular switch in various signaling pathways, influencing cellular organization and trafficking dynamics. The understanding of these regulatory mechanisms provides insights into the broader roles of ARL5 in cellular physiology, which could further elucidate its impact on the intracellular distribution and trafficking of critical cellular components.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a PKC activator which can indirectly activate ARL5 through the PKC pathway. PKC phosphorylates downstream targets in the pathway, allowing ARL5 to engage in vesicular trafficking with enhanced efficacy. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, elevating cAMP levels, and subsequently influencing PKA activation. PKA may phosphorylate targets that modulate ARL5 activity in vesicular trafficking. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Inhibits cAMP phosphodiesterase, leading to elevated cAMP levels and PKA activation. PKA can then potentially modulate proteins that interact directly with ARL5 in the vesicular trafficking process. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Calcium ionophore that raises intracellular calcium levels, possibly influencing calmodulin or other calcium-dependent proteins that can enhance ARL5 activity in vesicular trafficking. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Protein phosphatase inhibitor that retains the phosphorylation status of proteins, potentially maintaining ARL5 in an activated state. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $48.00 | ||
Elevates intracellular zinc levels, which can modulate metalloproteins that, in turn, may affect ARL5 functionality in vesicular sorting. | ||||||
Sodium Orthovanadate | 13721-39-6 | sc-3540 sc-3540B sc-3540A | 5 g 10 g 50 g | $49.00 $57.00 $187.00 | 142 | |
Phosphatase inhibitor that could preserve the phosphorylated state of proteins interacting with ARL5, thus possibly maintaining ARL5 activation. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
JNK pathway activator, which can phosphorylate substrates that may enhance ARL5-mediated vesicular trafficking. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor that blocks antagonistic pathways, thus possibly favoring pathways that keep ARL5 in an activated state. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Mimics cAMP and activates PKA, potentially leading to phosphorylation of proteins that positively modulate ARL5 activity. | ||||||